VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
Volition Unveils Its Epigenetic Toolbox
VolitionRx Announces Filing of Registration Statements
Volition Develops a New Improved Nu.Q™ Assay Format
VolitionRx Completes Acquisition of Octamer GmbH
VolitionRx Limited Announces Strategic Acquisition
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update